menten.ai

What It Is

Menten AI focuses on “generative AI + drug discovery.” Its core product, MAUD 1.0, is used to design cyclic peptide therapeutics / peptide macrocycles, aiming to address complex drug targets that are difficult for small molecules and traditional biologics to tackle—especially protein-protein interaction interfaces. According to the official website, its partners include Top-10 pharma companies, with Bristol Myers Squibb mentioned as an example, and it is backed by Social Impact Capital, Uncork Capital, Khosla Ventures, Y Combinator, and others.

Core Capabilities

MAUD 1.0 stands for Multi-parametric AI for Unbiased Design. Its key feature is combining generative AI, physics-based models, and quantum chemistry simulations to design macrocyclic peptides from scratch, rather than relying on traditional library screening. Its “physics-informed generative AI” approach emphasizes that it does not require large training datasets, while optimizing multiple drug-like properties at atomic-level precision, such as potency, permeability, and stability. Validation results disclosed on the website include nM-level potency, membrane/cellular permeability, favorable DMPK properties, in vivo efficacy, as well as oral bioavailability and a >90% hit rate mentioned on the homepage.

Pricing and Delivery

The collected information does not show any public pricing, free trial, plans, or payment methods, nor does it indicate a self-serve SaaS portal. Its business model appears closer to collaborative R&D / platform licensing for pharmaceutical companies and Biotech teams, with inquiries handled through “Partner with us.” No API, SDK, developer documentation, or enterprise system integration details are disclosed.

Pros and Cons

The strengths are a clear technical positioning, a focus on high-value peptide drug discovery scenarios, and the integration of generative models with physics and quantum simulations, which in theory can help reduce blind-screening costs and expand accessible chemical space. Its disclosed preclinical validation and collaborations with leading pharma companies also add credibility. The limitations are that the publicly available materials remain high-level: there is a lack of specific benchmarks, experimental scale, failure cases, target applicability boundaries, and reproducible evidence. Data privacy, project IP ownership, and compliance processes are also not explained in the main content.

Who It’s For and Access from China

It is suitable for pharmaceutical companies, Biotech teams, CRO collaboration groups, and computational drug design departments that have clear targets and experimental validation capabilities. It is not intended for ordinary individual users or teams looking for an out-of-the-box AI tool. Access from China cannot be determined from the text alone; website connectivity, contract payment, and cross-border data compliance need to be verified in practice. Comparable alternatives or adjacent options include Schrödinger, Insilico Medicine, Iktos, Exscientia, Generate Biomedicines, and traditional computational chemistry / CRO services.